Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;2(4):224-232.
doi: 10.1016/j.ajur.2015.08.007. Epub 2015 Sep 25.

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study

Affiliations

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study

Antonio Benito Porcaro et al. Asian J Urol. 2015 Oct.

Abstract

Objective: In prostate specimens, chronic inflammatory infiltrate (CII) type IV has been detected, but its association with prostate cancer (PCa) is controversial. The aim of the present study is to investigate on associations of CII with PCa detection in patients undergoing prostate first biopsy set.

Methods: Ultrasound transrectal-guided biopsies by the transperineal approach were retrospectively evaluated in 441 consecutive patients. The study excluded patients who were in active surveillance, prostate specific antigen (PSA) ≥30 ng/mL, re-biopsies, incidental PCa after transurethral resection of the prostate (TURP), less than 14 cores or metastatic. Analysis of population and subpopulations (with or without PCa) was performed by statistical methods which included Mann-Whitney (U test), Kruskal-Wallis test, Chi-squared statistic, logistic regression. Multivariate logistic regression models predicting mean probability of PCa detection were established.

Results: PCa detection rate was 46.03%. Age, PSA, prostate volume (PV), prostate intraepithelial neoplasia (PIN) and CII were the significant independent predictors of PCa detection. PV (OR = 0.934) and CII (OR = 0.192) were both negative independent predictors. CII was a significant negative independent predictor in multivariate logistic regression models predicting the mean probability of PCa detection by age, PSA and PV. The inverse association of CII with PCa does not necessary mean protection because of PSA confounding.

Conclusion: In a population of patients undergoing prostate first biopsy set, CII was a strong negative independent predictor of PCa detection. CII type IV should be considered as an adjunctive parameter in re-biopsy or active surveillance protocols.

Keywords: Biopsy Gleason score; Chronic inflammation; Prostate; Prostate biopsy; Prostate cancer; Prostate specific antigen; Prostate volume.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prostate biopsy indications. PSA, increased serum prostate specific antigen values; DRE, abnormal digital rectal exam with normal PSA values; DRE+PSA, both DRE and increased PSA; IMG, abnormal prostate imaging with normal PSA values.
Figure 2
Figure 2
Associations of CII with PCa. CII, chronic inflammatory infiltrate; PCa, prostate cancer.
Figure 3
Figure 3
Probability risk curves stratified by CII of the six models which are reported in Table 3. (A) CII associated with age; (B) CII interacting with age; (C) CII associated with PSA; (D) CII interacting with PSA; (E) CII associated with PV; (F) CII interacting with PV. CII, chronic inflammatory infiltrate; PCa, prostate cancer; PSA, total prostate specific antigen; PV, prostate volume.
Figure 4
Figure 4
Schematic mechanistic diagram showing the potential cellular exchange of signaling pathways towards inflammation in prostate cancer; prostatic intraepithelial neoplasia (PIN).

Similar articles

Cited by

References

    1. Selman A. The McNeal prostate: a review. Urology. 2011;78:1224–1228. - PubMed
    1. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Grönberg H., Drake C.G. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–269. - PMC - PubMed
    1. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60:199–215. - PMC - PubMed
    1. Bardia A., Platz E.A., Yegnasubramanian S., De Marzo A.M., Nelson W.G. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol. 2009;9:419–426. - PMC - PubMed
    1. Drake C.G. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–593. - PMC - PubMed